Overview

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

Status:
Unknown status
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Collaborator:
AstraZeneca
Treatments:
Afatinib
Erlotinib Hydrochloride
Gefitinib